An option deal with Roche (SIX:ROG; OTCQX:RHHBY) marks the first potential exit for early stage life science venture fund AmorChem and its in-house medicinal chemistry CRO, NuChem Therapeutics Inc.

The deal gives Roche an option for an exclusive, worldwide license to therapies for myotonic dystrophy 1 (Steinert disease) at the end of the collaboration. In total, AmorChem can collect $107 million with development and commercial milestones, plus single-digit tiered royalties.